During the last session, Y-Mabs Therapeutics Inc (NASDAQ:YMAB)’s traded shares were 0.32 million, with the beta value of the company hitting 0.63. At the end
Y-Mabs Therapeutics Inc (NASDAQ:YMAB)’s traded shares stood at 0.73 million during the last session, with the company’s beta value hitting 0.66. At the close of
In last trading session, Y-Mabs Therapeutics Inc (NASDAQ:YMAB) saw 0.33 million shares changing hands with its beta currently measuring 0.64. Company’s recent per share price
Y-Mabs Therapeutics Inc (NASDAQ:YMAB)’s traded shares stood at 0.59 million during the last session, with the company’s beta value hitting 0.64. At the close of
In last trading session, Y-Mabs Therapeutics Inc (NASDAQ:YMAB) saw 0.37 million shares changing hands with its beta currently measuring 0.66. Company’s recent per share price
During the last session, Y-Mabs Therapeutics Inc (NASDAQ:YMAB)’s traded shares were 0.75 million, with the beta value of the company hitting 0.65. At the end
During the last session, Y-Mabs Therapeutics Inc (NASDAQ:YMAB)’s traded shares were 1.07 million, with the beta value of the company hitting 0.66. At the end
Marketing Sentinel delivers exclusive content, news, articles, and comprehensive coverage of events in the USA and worldwide with a commitment to reliability, objectivity, and timeliness.
© 2024, Powered by Smart TechOne
